Fig. 2From: Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)Therapeutic timelines and schedule. (PD1, programmed cell death 1; TME, total mesorectal excision.)Back to article page